Aeterna Zentaris claims it booted CEO and then discovered a plot to grab control of its lead asset
A few weeks after Aeterna Zentaris’ lead drug Zoptrex flopped in a Phase III trial of endometrial cancer, the board and the CEO at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
